ArticleCancers2021
A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma.
Open access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Hidden secrets of the cancer genome: unlocking the impact of non-coding mutations in gene regulatory elements.Cellular and molecular life sciences : CMLS · 2024Review
- Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.British journal of cancer · 2024Article
- Polyamines: Key Players in Immunometabolism and Immune Regulation.Journal of cellular immunology · 2024Article
- Polyamines and Their Metabolism: From the Maintenance of Physiological Homeostasis to the Mediation of Disease.Medical sciences (Basel, Switzerland) · 2022Review
- Targeting Oncogenic Transcriptional Networks in Neuroblastoma: From N-Myc to Epigenetic Drugs.International journal of molecular sciences · 2021Review
- Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma MiceFrontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 15 institutions in 9 countries.
Laura D GambleChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.ORCID 0000-0001-8496-9705
Stefania PurgatoDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Michelle J HendersonChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.
Simone Di GiacomoDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0003-4409-2421
Amanda J RussellCancer Research Program, The Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.ORCID 0000-0001-7148-1081
Paolo PiginiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Jayne MurrayChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.
Emanuele ValliChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.
Giorgio MilazzoDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-1930-4763
Federico M GiorgiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-7325-9908
Mark CowleyChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.ORCID 0000-0002-9519-5714
Lesley J AshtonResearch Portfolio, University of Sydney, Sydney, NSW 2008, Australia.
Jaydutt BhalshankarSIREDO, Department of Paediatric, Adolescents and Young Adults Oncology and INSERM U830, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
Gudrun SchleiermacherSIREDO, Department of Paediatric, Adolescents and Young Adults Oncology and INSERM U830, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.ORCID 0000-0002-0133-5879
Ali RihaniCenter for Medical Genetics, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium.
Tom Van MaerkenCenter for Medical Genetics, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium.
Jo VandesompeleCenter for Medical Genetics, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium.ORCID 0000-0001-6274-0184
Frank SpelemanCenter for Medical Genetics, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium.
Rogier VersteegDepartment of Oncogenomics, Academic Medical Center, University of Amsterdam, 1100 Amsterdam, The Netherlands.
Jan KosterDepartment of Oncogenomics, Academic Medical Center, University of Amsterdam, 1100 Amsterdam, The Netherlands.ORCID 0000-0002-0890-7585
Angelika EggertDepartment of Pediatric Hematology, Oncology and SCT, Charité-University Hospital Berlin, Campus Virchow-Klinikum, 10117 Berlin, Germany.
Rosa NogueraDepartment of Pathology, Medical School, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0003-4546-7459
Raymond L StallingsMolecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, D02 YN77 Dublin 2, Ireland.
Gian Paolo ToniniNeuroblastoma Laboratory, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, 35127 Padova, Italy.
Kwun FongThoracic Research Centre, University of Queensland, The Prince Charles Hospital, Brisbane, QLD 4032, Australia.
Zalman VaksmanDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Sharon J DiskinDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Wendy B LondonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA 02215, USA.
Glenn M MarshallChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.
David S ZieglerChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.
Michael D HogartyDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-9221-4852
Giovanni PeriniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Murray D NorrisChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.ORCID 0000-0002-0632-4589
Michelle HaberChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Australia, PO Box 81, Randwick, NSW 2031, Australia.
Children's Cancer Institute Australia · AUUniversity of Bologna · ITChildren's Hospital of Philadelphia · USGhent University Hospital · BEAmsterdam UMC Location University of Amsterdam · NLInserm · FRCharité - Universitätsmedizin Berlin · DECittà della Speranza Foundation · ITGarvan Institute of Medical Research · AUHarvard University · USRoyal College of Surgeons in Ireland · IEThe University of Queensland · AUThe University of Sydney · AUUniversitat de València · ESUNSW Sydney · AU
Funding
Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomesR35CA220500 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI JOHN M MARIS · 2017 to 2026
$8.7MCancer Council NSW PG16-01Cancer Institute NSW 12/TPG/1-13Italian Association for Research on Cancer IG11400Italian Association for Research on Cancer IG15182National Health and Medical Research Council APP1132608NCI NIH HHS R35 CA220500NIH HHS R35 CA220500 and R01 CA124709Research Foundation - Flanders FWO/1803115NUniversiteit Gent BOF/01D02210
Abstract
Ornithine decarboxylase (ODC1), a critical regulatory enzyme in polyamine biosynthesis, is a direct transcriptional target of MYCN, amplification of which is a powerful marker of aggressive neuroblastoma. A single nucleotide polymorphism (SNP), G316A, within the first intron of
Indexed as
MYCNneuroblastomaODC1SNP
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.